Loading…
Surrozen, Inc. is projected to rise to $28.91 by 2027, a +25% move from its current price of $23.19. SRZN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $22.52 | $23.21 | $23.91 | +0.07% |
| Jul 14 | $22.26 | $23.22 | $24.23 | +0.14% |
| Jul 15 | $22.06 | $23.24 | $24.48 | +0.21% |
| Jul 16 | $21.90 | $23.26 | $24.70 | +0.28% |
| Jul 17 | $21.76 | $23.27 | $24.89 | +0.35% |
| Jul 18 | $21.63 | $23.29 | $25.07 | +0.42% |
| Jul 19 | $21.52 | $23.30 | $25.23 | +0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $21.52 | $23.30 | $25.23 | +0.49% |
| Week 2 | $20.93 | $23.42 | $26.21 | +0.99% |
| Week 3 | $20.51 | $23.54 | $27.01 | +1.49% |
| Week 4 | $20.17 | $23.65 | $27.73 | +1.99% |
| Week 5 | $19.89 | $23.77 | $28.40 | +2.49% |
| Week 6 | $19.66 | $23.89 | $29.03 | +3.00% |
| Week 7 | $19.45 | $24.00 | $29.63 | +3.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Surrozen, Inc. is a biotechnology company that discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases.
Surrozen has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen was founded in 2015 and is headquartered in South San Francisco, California.
Surrozen, Inc. (SRZN) is a biotechnology company with a current price of $23.01 and a market cap of $267.15M. It is ranked 3613.
The asset's price action and fundamentals are tracked with a current price of $23.01 and a market cap of $267.15M, ranking 3613 among peers. The price outlook is informed by a forecast that starts with a 2026 average price of $23.01 and rises through subsequent years, signaling a bullish longer-term trajectory. The forecast highlights notable upside in later years, with the 2040 and 2050 averages showing substantial gains and corresponding ROI expansion.
A major floor 23.1% below — a decisive break under it would weaken the trend.
The nearest floor, 10.8% below — buyers have tended to step in here.
The nearest ceiling, 13.0% above — a clean break opens room to run.
A major ceiling 47.2% above — clearing it would confirm fresh momentum.
Key SRZN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SRZN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $23.25 | Sell | $23.49 | Sell |
| MA 10 | $24.36 | Sell | $23.84 | Sell |
| MA 20 | $24.07 | Sell | $24.17 | Sell |
| MA 50 | $26.15 | Sell | $25.25 | Sell |
| MA 100 | $26.99 | Sell | $25.11 | Sell |
| MA 200 | $22.20 | Buy | $22.51 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.61 | Neutral |
| Stoch RSI (14) | 15.89 | Buy |
| CCI (20) | -65.25 | Neutral |
| Williams %R (14) | -89.90 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -6.72 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 10.10 | Buy |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | -0.93 | Sell |
| Ultimate (7,14,28) | 29.15 | Buy |
| Momentum (10) | -1.33 | Sell |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 22.57 | Buy |
| ADX (14) | 13.50 | Neutral |
| ATR (14) | 0.66 | Info |
The near-term technical picture is labeled BULLISH. RSI(14) is 40, while the near-term moving averages show SMA50 at $26.54 and SMA200 at $22.03. Support is placed at $20.69 and resistance at $26.46, framing a defined near-term range.
The 30-day range for SRZN spans from $18.59 to $28.48, reflecting ongoing volatility within a bullish backdrop. Annualized volatility is 60%, underscoring elevated variance in recent price moves while the longer-term trend remains positive according to the current sentiment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $17.98 | $23.19 | $32.74 | 0% | Neutral | |
| $22.80 | $28.91 | $38.91 | +25% | Bullish | |
| $25.30 | $33.09 | $46.36 | +43% | Bullish | |
| $24.97 | $33.51 | $48.45 | +45% | Bullish | |
| $25.25 | $34.68 | $51.46 | +50% | Bullish | |
| $27.02 | $37.88 | $57.53 | +63% | Bullish | |
| $32.22 | $46.07 | $71.40 | +99% | Bullish | |
| $38.20 | $55.63 | $87.84 | +140% | Bullish | |
| $38.92 | $57.68 | $92.64 | +149% | Bullish | |
| $40.51 | $61.04 | $99.61 | +163% | Bullish | |
| $58.88 | $95.76 | $166.91 | +313% | Bullish | |
| $84.70 | $157.36 | $301.86 | +579% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $17.98 | $23.19 | $28.60 | +0.00% |
| August 2026 | $21.08 | $24.95 | $30.36 | +7.57% |
| September 2026 | $20.73 | $24.73 | $30.47 | -0.87% |
| October 2026 | $20.53 | $24.65 | $30.68 | -0.32% |
| November 2026 | $21.16 | $25.54 | $32.07 | +3.63% |
| December 2026 | $21.32 | $25.87 | $32.74 | +1.29% |
Click any year to see its month-by-month SRZN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Surrozen, Inc.'s 2026 outlook centres on $23.19, within a $17.98 to $32.74 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, SRZN could reach as high as $38.91, with a base case around $28.91 and support toward $22.80 — roughly +25% from $23.19. Buyers look set to stay in control over this stretch.
Expect SRZN to range from $25.30 to $46.36 through 2028. The $33.09 average target implies a +43% move from current prices. That is up +14% on the projected 2027 average. Momentum favours further upside here.
The SRZN price prediction for 2029 points to an average of $33.51 (low $24.97, high $48.45) — a potential gain of +45% on today's $23.19. Buyers look set to stay in control over this stretch.
In 2030, SRZN is projected to trade between $25.25 and $51.46, averaging $34.68 — a potential gain of +50% from today's $23.19. That is up +3% on the projected 2029 average. Momentum favours further upside here.
Surrozen, Inc.'s 2031 outlook centres on $37.88, within a $27.02 to $57.53 range. That is up +9% on the projected 2030 average. That marks a +63% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, SRZN could reach as high as $71.40, with a base case around $46.07 and support toward $32.22 — roughly +99% from $23.19. Momentum favours further upside here.
Expect SRZN to range from $38.20 to $87.84 through 2033. The $55.63 average target implies a +140% move from current prices. That is up +21% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The SRZN price prediction for 2034 points to an average of $57.68 (low $38.92, high $92.64) — a potential gain of +149% on today's $23.19. Momentum favours further upside here.
In 2035, SRZN is projected to trade between $40.51 and $99.61, averaging $61.04 — a potential gain of +163% from today's $23.19. That is up +6% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Surrozen, Inc.'s 2040 outlook centres on $95.76, within a $58.88 to $166.91 range. That is up +57% on the projected 2035 average. That marks a +313% change versus current levels. Momentum favours further upside here.
By 2050, SRZN could reach as high as $301.86, with a base case around $157.36 and support toward $84.70 — roughly +579% from $23.19. Buyers look set to stay in control over this stretch.
Investing $1,000 in SRZN today (≈ 43.122035 SRZN) could be worth
$6,785.79
+$5,785.79 (+579%) by 2050 · US Dollar
Based on the average projected SRZN price of $157.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SRZNwould be worth at today's price.
$1,000 invested in SRZN on Jul 10, 2025 (≈ 116.686119 SRZN) would be worth
$2,705.95
+$1,705.95 (+170.6%) today · 2.71× · US Dollar
Based on a SRZN entry price of $8.57 vs. today's $23.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24.92 | $930.58 | -6.9% |
| 1 month ago | $21.77 | $1,065.23 | +6.5% |
| 3 months ago | $28.2 | $822.34 | -17.8% |
| 6 months ago | $18 | $1,288.33 | +28.8% |
| 1 year ago | $8.57 | $2,705.95 | +170.6% |
| All time (5.0y) ago | $149.1 | $155.53 | -84.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SRZN forecast.
Our base-case forecast reaches $46.00 around 2032.
Implied market cap at $46.00: $534.08M
The multi-year forecast depicts a rising trajectory across the next several years. In 2026, the min price is $17.98, the avg is $23.01, and the max is $32.84, with ROI 0 and sentiment Neutral.
From 2027 onward, the averages trend higher: 2027 avg $28.97, 2028 avg $33.64, 2029 avg $33.66, 2030 avg $34.96, 2031 avg $38.95, 2032 avg $47.64, 2033 avg $58.06, 2034 avg $60.30, and 2035 avg $63.34, with progressive ROIs of 25.9, 46.2, 46.3, 51.9, 69.3, 107.1, 152.3, 162.1, and 175.3 respectively, all in a bullish sentiment context.
Looking further out, 2040 shows an avg of $102.30 with ROI 344.6 and a max of $182.85, while 2050 shows an avg of $165.78 with ROI 620.5 and a max of $327.53, continuing the bullish tilt. These figures illustrate a long-term rise in anticipated value, though they are estimates and not guarantees. The forecast also notes a shift to bullish sentiment in later years, emphasizing potential upside alongside significant uncertainty and volatility.
Tap a question to reveal the answer.
In 2030 the forecast lists min $25.08, avg $34.96, max $52.76 with ROI 51.9 and sentiment BULLISH.
The forecast shows rising averages and bullish sentiment from 2027 onward, with ROI reaching 69.3% in 2031 and up to 620.5% by 2050, but these are estimates and not guarantees.
Yes in the forecast, with a 2031 max of $60.21, 2032 max $75.27, 2033 max $93.53, 2040 max $182.85, and 2050 max $327.53.
Current price is $23.01 and market cap is $267.15M.
The 30-day range is $18.59 to $28.48.
Surrozen, Inc. Community Discussion
0Share your Surrozen, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.